Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Patrick Forde

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Journal of Thoracic Oncology

English

Sequential Occurrence of a Splenic Marginal Zone Lymphoma, Extranodal MALT Lymphoma, and Hodgkin Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

Related publications

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology

English

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

Journal of Thoracic Oncology

English

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

Journal of Thoracic Oncology

English

P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

Journal of Thoracic Oncology

English

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

Journal of Thoracic Oncology

English

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

Journal of Thoracic Oncology

English

OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Journal of Thoracic Oncology

English

P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Patrick Forde

Characterization of 298 Patients With Lung Cancer Harboring MET Exon 14 Skipping Alterations

Sequential Occurrence of a Splenic Marginal Zone Lymphoma, Extranodal MALT Lymphoma, and Hodgkin Lymphoma

Related publications

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Brief Report: DNA-based Versus RNA-based Detection of MET Exon 14 Skipping Events in Lung Cancer

OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress

P1.13-41 in Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers With MET Mutations Including Exon 14 Skipping

OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations

P3.09-18 Identification of MET Exon 14 Skipping Mutations by FusionPlexTM Solid Tumor Panel

OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

P1.01-74 MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition